The Cell, Gene, & Immunotherapy event is for manufacturing efficiencies, cost, and quality. 

Accelerate your bioprocessing, analytics, supply chain security and commercialization strategies by accessing novel science, technologies and the contacts you need

For more than 10 years, The Bioprocessing Summit has been recognized as the premier forum for industry leaders to share the latest research in bioprocess R&D, scale-up, quality and analytics.

The American Association for Laboratory Animal Science (AALAS) is a membership association of professionals employed around the world in academia, government, and private industry who are dedicated to the humane care and treatment of laboratory animals, as well as the quality research that leads to scientific gains

The Cell & Gene Meeting on the Mesa is the sector's foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures.

Editas Medicine, Inc. EDIT is making good progress with the development of its lead pipeline candidate, EDIT-101, which employs CRISPR gene editing, to treat Leber congenital amaurosis type 10 (LCA10) — a rare genetic illness that causes blindness.

New York City has set up a new advisory panel of developers, brokers and investors to advise how the city's real estate can be leveraged to better serve and grow its nascent life sciences industry.

TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the appointment of Eric Sullivan as Chief Financial Officer where he will be responsible for leading all aspects of financial management and capital market strategy as well as overseeing investor relations and select business operations.

 Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that new research highlighting the company’s internal efforts to develop improved transplant conditioning regimens for patients with sickle cell disease (SCD) undergoing hematopoietic stem cell transplantation (HSCT) will be presented today, June 27, 2022, at

See SmartLabs in Action!

See SmartLabs in Action!

Revolutionizing cell and gene engineering - ground breaking autologous and allogeneic treatments for blood borne and solid tumors

- Advances in oRNA expression and delivery enable pipeline of therapeutics across a diverse range of disease areas

- Lead is CAR program shows possibility of tumor eradication in preclinical animal models with promise of translation to non-human primates and patients